Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) insider Reshma P. Shetty has recently sold 37,650 shares of Ginkgo Bioworks stock in a transaction that took place on Wednesday, September 13th. The shares were sold at an average price of $2.04, resulting in a total value of $76,806.00. After the transaction, Shetty now holds 12,901,654 shares of the company’s stock, with an approximate value of $26,319,374.16. This transaction was disclosed in a legal filing with the SEC.
On Friday, September 17th, shares of Ginkgo Bioworks traded down to $1.93 during mid-day trading. The company reported a trading volume of 29,755,443 shares compared to its average volume of 21,343,533. With a market cap of $4.05 billion and a price-to-earnings ratio of -2.72, Ginkgo Bioworks has displayed considerable volatility in its stock price since its inception.
Ginkgo Bioworks Holdings specializes in cell programming technology and develops platforms for biological production of various products including therapeutics, food ingredients, and chemicals derived from petroleum. With applications across multiple industries such as specialty chemicals, agriculture, food production, consumer products, and pharmaceuticals; Ginkgo Bioworks aims to revolutionize these sectors through innovative cell programming solutions.
In terms of hedge fund activity surrounding Ginkgo Bioworks stock holdings have been modified by several firms recently.
For instance:
– Arizona State Retirement System raised their holdings by 41.7% during the fourth quarter.
– Y Intercept Hong Kong Ltd made a new stake in Ginkgo Bioworks during the first quarter.
– Green Alpha Advisors LLC also made a new stake during the same period.
– Similarly,Powell Investment Advisors LLC made a new stake valued at $57,000 during the first quarter.
Institutional investors collectively own 56.84% of Ginkgo Bioworks stock, pointing towards growing interest from experienced market participants.
While the company has seen fluctuations in its share price, it continues to focus on advancing its cell programming platform and expanding its presence across various industries. Given its diverse applications and innovative approach, Ginkgo Bioworks may continue to attract attention from both investors and strategic partners in the coming months.
Ginkgo Bioworks Holdings, Inc.
DNA
Neutral
Updated on: 03/12/2023
Financial Health
Weak
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Sell
Ginkgo Bioworks Faces Financial Struggles as Negative Net Margin and Return on Equity Stir Concerns
Ginkgo Bioworks Holdings, Inc, a leader in the field of cell programming, recently released its quarterly earnings results, leaving investors and analysts perplexed. The company posted an EPS of ($0.09) for the quarter, which was in line with analysts’ consensus estimates. However, what caught the attention of many was the negative net margin of 375.48% and a negative return on equity of 66.58%. With these figures in mind, it becomes clear that Ginkgo Bioworks is facing significant challenges.
Despite this disappointing performance, Ginkgo Bioworks remains committed to its mission of developing a platform for cell programming. This platform allows cells to be programmed for various purposes, including the production of therapeutics, food ingredients, and chemicals derived from petroleum. The company serves a wide range of industries such as specialty chemicals, agriculture, food production, consumer products, and pharmaceuticals.
In light of their recent financial results, several equity analysts have issued reports on Ginkgo Bioworks. The Goldman Sachs Group downgraded the company from a “neutral” rating to a “sell” rating and reduced their price target from $3.00 to $1.25. Similarly, Raymond James dropped their target price on Ginkgo Bioworks shares from $5.00 to $3.50 but maintained an “outperform” rating.
Currently, one analyst has rated the stock as a sell while two have assigned it a hold rating and two have given it a buy rating. According to Bloomberg data analysis as of September 17th, Ginkgo Bioworks has an average rating of “Hold” and a consensus target price of $3.
It remains unclear what factors contributed to the negative financial performance reported by Ginkgo Bioworks during this fiscal year thus far. Investors and analysts alike are eagerly awaiting further updates from the company regarding its plans to address these challenges and revamp its financial outlook.
In conclusion, Ginkgo Bioworks Holdings, Inc’s recent quarterly earnings have raised concerns among investors due to its negative net margin and return on equity. While the company continues to develop its cell programming platform for various industries, it will need to address its financial struggles and provide a clearer path forward for investors. The overall sentiment of analysts is cautious, with a “Hold” rating currently dominating the consensus. Only time will tell if Ginkgo Bioworks can regain momentum in the market.
Discussion about this post